Eli Lilly and’s (LLY) “Buy” Rating Reiterated at Berenberg Bank
Other equities analysts have also recently issued reports about the stock. TheStreet upgraded shares of Eli Lilly and from a c+ rating to a b+ rating in a research note on Tuesday, July 25th. Citigroup Inc. boosted their price target on shares of Eli Lilly and from $92.00 to $100.00 and gave the company a buy rating in a report on Wednesday, April 19th. Jefferies Group LLC reissued a buy rating and issued a $97.00 price target on shares of Eli Lilly and in a report on Monday, April 10th. Zacks Investment Research raised shares of Eli Lilly and from a hold rating to a buy rating and set a $96.00 price target on the stock in a report on Wednesday, April 12th. Finally, Piper Jaffray Companies reissued a buy rating and issued a $100.00 price target on shares of Eli Lilly and in a report on Monday, April 17th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company. The company has an average rating of Hold and an average target price of $88.27.
Eli Lilly and (LLY) opened at 82.03 on Friday. The firm’s 50-day moving average is $82.99 and its 200 day moving average is $81.53. Eli Lilly and has a one year low of $64.18 and a one year high of $86.72. The firm has a market capitalization of $86.54 billion, a price-to-earnings ratio of 35.50 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.86 EPS. Analysts forecast that Eli Lilly and will post $4.16 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Eli Lilly and’s (LLY) “Buy” Rating Reiterated at Berenberg Bank” was first posted by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/08/07/eli-lilly-ands-lly-buy-rating-reiterated-at-berenberg-bank.html.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be issued a dividend of $0.52 per share. The ex-dividend date is Friday, August 11th. This represents a $2.08 annualized dividend and a yield of 2.53%. Eli Lilly and’s dividend payout ratio (DPR) is currently 90.04%.
In other news, VP Michael J. Harrington sold 22,833 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the transaction, the vice president now directly owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the transaction, the insider now directly owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The disclosure for this sale can be found here. Insiders have sold a total of 669,733 shares of company stock worth $55,845,287 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in LLY. Vanguard Group Inc. boosted its position in Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after buying an additional 2,181,701 shares in the last quarter. BlackRock Inc. boosted its position in Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after buying an additional 59,978,664 shares in the last quarter. State Street Corp boosted its position in Eli Lilly and by 1.6% in the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock valued at $3,563,230,000 after buying an additional 651,424 shares in the last quarter. Geode Capital Management LLC boosted its position in Eli Lilly and by 8.4% in the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock valued at $764,597,000 after buying an additional 708,597 shares in the last quarter. Finally, Janus Capital Management LLC boosted its position in Eli Lilly and by 2.8% in the first quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock valued at $733,731,000 after buying an additional 237,619 shares in the last quarter. 75.61% of the stock is owned by institutional investors and hedge funds.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.